Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.48 |
| ▸ | PDE4A | P27815 | 4/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886712 | 1.00 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CCNR1 | |
| SCHEMBL2886529 | 0.91 | PDE4B (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL2886527 | 0.91 | PDE4B (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL2887030 | 0.91 | PDE4D (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2887026 | 0.91 | PDE4D (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2887949 | 0.91 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2887953 | 0.91 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2887024 | 0.91 | PDE4D (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2887955 | 0.91 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CHPGD | |
| SCHEMBL2881473 | 0.88 | PDE4D (0.51) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | PDE4B 1585/4885PDE4D 1854/4885PDE4A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.